Although it is well known that mutations in genes like Von Hippel-Lindau (VHL) associated with the development of ccRCC, and there are many RNA and protein markers associated with prognosis in patients with ccRCC, currently, there is no reliable prognostic biomarker which can be used in clinical practice [25, 26]. Here, VHL is linked to nonpapillary renal cell carcinoma.